Article | September 1, 2022

A Faster And More Economical Path To Investigational New Drug Applications

By William C. Barrett, Ph.D. and Doug Puzia

Time is money hourglass GettyImages-1325703070

It is a long, expensive, risky, and time-consuming process to get a drug ready for an investigational new drug (IND) application. With many companies developing competing molecules for the same indications, the potential to make billions can come down to who gets their drug through FDA clearance first. A few weeks can make a big difference in the sales needed to recoup the investment.

With all that is at stake, biopharma companies are looking for smarter and more flexible paths to IND. They not only want to reach this stage faster but also need to get more molecules ready for an IND application to increase their chances of success. With a smaller footprint and faster cycle times, new membrane-based protein A affinity chromatography technology can greatly shorten the time it takes to get to IND while also making the process less expensive and more adaptable.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online